Nucleic acid and mRNA solutions provider TriLink BioTechnologies, a subsidiary of Maravai LifeSciences (NASDAQ: MRVI), announced on Monday that it has partnered with Avantor Inc (NYSE: AVTR) to expand the availability of its advanced nucleic acid products across Europe, the Middle East and Africa (EMEA).

The partnership aims to streamline the ordering process and reduce lead times, enhancing support for customer projects from development to delivery.

With over 25 years of experience, TriLink offers a range of products, including CleanCap cap analogs, catalog mRNAs, over 150 nucleotides and high-performance IVT enzymes like CleanScribe RNA Polymerase. These can be customised for research use or manufactured at GMP-grade. Availability through Avantor's VWR eCommerce platform, MarketSource, is planned for the coming months.

TriLink's expertise in nucleic acid therapeutics and vaccine development has positioned it as a leader in supporting pharmaceutical innovations, including COVID-19 vaccine production and advanced oncology treatments. The collaboration with Avantor strengthens its ability to serve the growing demand for nucleic acid technologies across EMEA markets.

Avantor, a global provider of life science tools, operates in over 180 countries and plays a critical role in scientific advancements, from drug development to breakthrough healthcare technologies.